Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The usual approach to managing HPV-related oropharynx cancer in people whose tumors have a higher risk of coming back after surgery is to use radiation therapy to prevent tumor relapse. However, not all patients have tumors that come back after surgery, and many may not need radiation therapy at all, or only need it later when there are early signs of the cancer coming back.
Researchers want to find the best dose of Debio 0123 that can be given with temozolomide to treat glioblastoma. Glioblastoma is a type of brain cancer. The people in this study have glioblastoma that keeps growing even after treatment.
Researchers are assessing a combination of medications to see if they work well against upper digestive cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that spread and keep growing after treatment.
Researchers are seeking the best dose of cirtuvivint to use alone and with ASTX727 for leukemia and myelodysplastic syndromes (MDS). The people in this study have acute myeloid leukemia (AML) or MDS that keeps growing after treatment.
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
Researchers are seeking the best dose of CLSP-1025 to use in people with advanced solid tumors. The people in this study have cancers with a mutation (change) in the p53 gene called R175H. They are also positive for a specific human leukocyte antigen (HLA type A*0201). HLA is a protein on cells that plays an important role in the immune response to foreign substances.
Researchers want to see if giving stereotactic radiosurgery (SRS) after osimertinib is better than osimertinib alone for advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that metastasized (spread) to the brain. Their cancers have a mutation (change) in the EGFR gene, and they are taking or planning to take osimertinib.
Plasmablastic lymphoma is a type of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study is to determine if adding daratumumab to a standard chemotherapy regimen (DA-EPOCH) is a safe way to increase the effectiveness of treatment in people with plasmablastic lymphoma.   
Researchers want to find the best dose of STP938 to treat lymphoma and see how well this drug works against this cancer. The people in this study have B-cell or T-cell lymphoma that keeps growing even with treatment. Examples of these cancers include:
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
